Cardiva Medical, Inc.
$741.8K 7,304 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
OPKO Pharmaceuticals, LLC
OPKO Pharmaceuticals, LLC reported $740,736.66 across General Payments, Research, and Ownership to 6,592 physicians and teaching hospitals across 6,610 transactions.
- $740.7K Above-median payer
- All-tracks total
- 6,610 Top quartile volume
- Transactions
- 6,592 Top quartile reach
- Recipients
- +$8.2K
- General Payments vs PY2023
OPKO Pharmaceuticals, LLC reported $740,736.66 across all CMS Open Payments tracks (General + Research + Ownership) to 6,592 physicians and teaching hospitals in Program Year 2024 - ranking #684 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $235,664.88, averaging $112.37 per recipient.
How OPKO Pharmaceuticals, LLC's $740.7K all-tracks total breaks down
OPKO Pharmaceuticals, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
53/100
Total payments
F
17/100
Transaction volume
D
58/100
Physician reach
D
60/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer opko-pharmaceuticals-llc OPKO Pharmaceuticals, LLC
$740.7K · #684/1,925 · 0.0% industry · PY2024
- TOT $740.7K
- RANK #684
- SHARE 0.0%
- TXN 6,610
- RCP 6,592
- CAT 6
- GEN $235.7K
- ΔGEN +$8.2K
- TOP1 10.6%
- PY 2024
Volume peers
Nearest volume peer: Cardiva Medical, Inc. ($741.8K)
OPKO Pharmaceuticals, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
OPKO Pharmaceuticals, LLC's CMS-reported General Payments increased by $8.2K (+3.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OPKO PHARMACEUTICALS, LLCPY2023: OPKO PHARMACEUTICALS, LLCPY2024: OPKO Pharmaceuticals, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $227,452.76
- PY2024
- $235,664.88
What the Data Shows for OPKO Pharmaceuticals, LLC
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For OPKO Pharmaceuticals, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
38 transactions worth $99.9K make "Compensation for Services Other Than Consulting" the top general-payment category in the 6-category breakdown below, 42.4% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 6 types of general payments, OPKO Pharmaceuticals, LLC's largest category was "Compensation for Services Other Than Consulting" at $99.9K - 42.4% of General Payments.
OPKO Pharmaceuticals, LLC reports 6 general-payment categories - the top three are Compensation for Services Other Than Consulting (42.4%), Food and Beverage (31.3%), and Education (17.9%). The remaining 3 categories make up 8.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How OPKO Pharmaceuticals, LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $99.9K | 38 | 42.4% |
| Food and Beverage | $73.7K | 4,107 | 31.3% |
| Education | $42.1K | 2,422 | 17.9% |
| Honoraria | $11.9K | 9 | 5.0% |
| Consulting Fee | $8.0K | 7 | 3.4% |
| Travel and Lodging | $158.05 | 9 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $90,086.76 (38.2%) of $235,664.88 in this company's General Payments records across 2,088 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for OPKO Pharmaceuticals, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Varshasb Broumand
$24,893.42 across 54 reported transactions
- 2
Ronald Levy
$20,000.00 across 2 reported transactions
- 3
John Heymach
$20,000.00 across 2 reported transactions
- 4
Eric Rubin
$14,600.00 across 7 reported transactions
- 5
Harry Dounis
$10,593.34 across 17 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
OPKO Pharmaceuticals, LLC ranks #684 of 1,925 by total payments (top 36% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,420 of 1,838 by HHI (bottom 23% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- United Therapeutics Corporation : $4.3M total payments, HHI 355
- Dornier MedTech America, Inc : $4.3K total payments, HHI 354
- Moximed, Inc : $1.8K total payments, HHI 353
- Edwards Lifesciences Corporation : $27.8M total payments, HHI 353
- Endo USA, Inc. : $1.5M total payments, HHI 351
- Thommen Medical USA, LLC : $89.6K total payments, HHI 351
- OPKO Pharmaceuticals, LLC (this company) : $235.7K total payments, HHI 350
- Teleflex LLC : $5.6M total payments, HHI 349
- Carl Zeiss Meditec USA, Inc. : $719.3K total payments, HHI 348
- Checkpoint Surgical, Inc : $293.7K total payments, HHI 348
- Medline Industries LP : $1.9M total payments, HHI 347
- Olympus Corporation : $904.0K total payments, HHI 343
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as OPKO Pharmaceuticals, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about OPKO Pharmaceuticals, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with OPKO Pharmaceuticals, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Intera Oncology, Inc
$739.7K 313 recipients
Compare payment profiles
Gyrus ACMI, Inc.
$738.6K 91 recipients
Compare payment profiles
La Jolla Pharmaceutical Company
$746.9K 3,634 recipients
Compare payment profiles
TightLine Development, LLC
$750.0K 1 recipients
Compare payment profiles
Carl Zeiss Meditec USA, Inc.
$719.3K 2,435 recipients
Compare payment profiles
Put this to use
OPKO Pharmaceuticals, LLC ranks #684 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just OPKO Pharmaceuticals, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.